febrile seizures plus (GEFS+) type 1 (2) . The SCN1B-C121W mutation affects a highly conserved cysteine residue that normally forms a disulfide bridge that is critical for maintaining the Ig loop. Subsequently, other heterozygous mutations in SCN1B have been identified, with the majority located in the Ig loop domain (1) .
Although it was first reported almost 20 years ago, there is still active investigation into the mechanisms of how the SCN1B-C121W mutation leads to epilepsy. The initial report demonstrated that the coexpression of the mutant β1-C121W and α subunits in Xenopus oocytes resulted in biophysical differences in sodium conductance that suggested loss of its modulatory effect on the α subunit (2) . Similar effects were observed in mammalian cell lines (3) (4) (5) . Additionally, the SCN1B-C121W mutation results in the loss of cell-adhesion properties, while plasma membrane trafficking functions are preserved (3) (4) (5) (6) (7) . Studies of the mutation effect in heterologous systems have been informative; however, they do not reveal the complete picture of how the SCN1B-C121W mutation acts within the nervous system.
More recent studies have addressed this issue using knock-in mouse models. Neurons are highly polarized cells with many important functional subdomains. A domain of particular importance for neuronal excitability and epilepsy is the axon initial segment (AIS), which is the site of action Voltage-gated sodium channel (VGSC) β subunits signal through multiple pathways on multiple time scales. In addition to modulating sodium and potassium currents, β subunits play nonconducting roles as cell adhesion molecules, which allow them to function in cell-cell communication, neuronal migration, neurite outgrowth, neuronal pathfinding, and axonal fasciculation. Mutations in SCN1B, encoding VGSC β1 and β1B, are associated with epilepsy. Autosomaldominant SCN1B-C121W, the first epilepsy-associated VGSC mutation identified, results in genetic epilepsy with febrile seizures plus (GEFS+). This mutation has been shown to disrupt both the sodium-current-modulatory and cell-adhesive functions of β1 subunits expressed in heterologous systems. The goal of this study was to compare mice heterozygous for Scn1b-C121W (Scn1b +/W ) with mice heterozygous for the Scn1b-null allele (Scn1b +/− ) to determine whether the C121W mutation results in loss-of-function in vivo. We found that Scn1b +/W mice were more susceptible than Scn1b
and Scn1b +/+ mice to hyperthermia-induced convulsions, a model of pediatric febrile seizures. β1-C121W subunits are expressed at the neuronal cell surface in vivo. However, despite this, β1-C121W polypeptides are incompletely glycosylated and do not associate with VGSC α subunits in the brain. β1-C121W subcellular localization is restricted to neuronal cell bodies and is not detected at axon initial segments in the cortex or cerebellum or at optic nerve nodes of Ranvier of Scn1b W/W mice. These data, together with our previous results showing that β1-C121W cannot participate in transhomophilic cell adhesion, lead to the hypothesis that SCN1B-C121W confers a deleterious gain-of-function in human GEFS+ patients. samples was approximately half of that observed in wild-type controls, and migrated at a lower molecular weight. PNGaseF digestion to remove N-linked glycosylation ameliorated the apparent molecular weight difference, indicating incomplete glycosylation of the β1-C121W mutant protein. The reduction in β1 protein remained consistent across a range of ages from postnatal day 14 through ≥ 20 weeks of age. Using cell surface biotinylation assays, they demonstrated that the mutant β1-C121W protein was present at the cell surface. However, immunocytochemistry experiments showed that β1-C121W was excluded from specialized sites of enriched wild-type β1 expression, including the AIS and nodes of Ranvier. Exclusion of β1-C121W from the AIS was observed in multiple brain regions, including cortical layers II and IV and cerebellar Purkinje neurons. Furthermore, coimmunoprecipitation experiments demonstrated that the mutant β1-C121W did not associate with sodium channel α subunits.
Sodium Channel β Subunits in
Based on their findings, the authors propose that the Scn1b +/W mutation is not a simple loss-of-function but rather a gain-of-function. They speculate that presence of the mutant β1-C121W protein on the soma may effectively dilute the density of wild-type β1 subunits and reduce their function. Based on this postulation, it may be more accurate to designate Scn1b +/W as a dominant negative or antimorphic mutation.
Regardless of semantics, this study reiterates the essential role of the β1 subunit in neuronal function and suggests that the amount of functional β1 may be a critical determinant of neuronal excitability. This suggests the possibility that natural variation in the level of β1 expression may buffer some individuals against deleterious effects of heterozygous SCN1B mutations, and may explain some of the variable penetrance and expressivity observed in families with SCN1B mutations. Additionally, it suggests that upregulation of the wild-type allele may have therapeutic benefit for SCN1B epilepsy mutations.
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